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Abstract
Gastrointestinal stromal tumour (GIST) is a rare tumour 
of the gastrointestinal tract which does not generally 
originate in the rectum. The authors describe a case of 
a 70-year-old man who underwent an anterior resection 
of the rectum for a low-risk GIST. The patient was not 
given adjuvant chemotherapy with imatinib and is still 
disease-free 30 mo after surgery. The authors conclude 
that although rectal GIST is extremely uncommon, 
it should be included in differential diagnosis when a 
tumour in the rectum is detected. Biopsy of the tumour 
is essential, since this makes it possible to reach a sure 
preoperative diagnosis based on the immunohistological 
features of the CD117 and CD34. Although complete 
surgical resection with negative tumour margins is 
the principal curative procedure for primary and non-
metastatic tumours, further studies are still needed 
for the determination of the most effective treatment 
strategy for patients with rectal GIST.
© 2008 WJG. All rights reserved.
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INTRODUCTION
Gastrointestinal stromal tumour (GIST) is a rare 
tumour involving the gastrointestinal tract and expresses 
CD117, a c-kit proto-oncogene, which can be detected 
immunohistochemically[1,2]. The most common GIST 
sites are the stomach (60%-70%) followed by the small 
intestine (20%-25%), whereas only about 5% of  all GISTs 
start in the rectum[3,4]. Rectal GISTs make up 0.1% of  all 
tumours originating in the rectum. According to a recent 
epidemiological investigation conducted in the USA, their 
incidence is 6.8 per million people annually[3,5]. In this 
report, the authors describe a rare case of  GIST of  the 
rectum.
CASE REPORT
A 70-year-old man was refer red to our hospita l 
complaining of  a dragging sensation in the rectum and 
several episodes of  rectal pain, without any problems 
of  the alvus. A clinical examination did not detect any 
palpable abdominal mass. Digital investigation of  the 
rectum revealed a mass of  approximately 4 cm in diameter 
on the left lateral rectal wall at about 2 cm above the 
dentate line. The mass was hard, elastic and immobile, 
with an irregular surface. No blood was found on the 
exploratory finger. A provisional diagnosis of  rectal 
carcinoma was made and a colonoscopy was programmed. 
This examination confirmed the presence of  a mass, 
probably of  submucous origin, measuring about 4 cm in 
its maximum diameter, attached to the lateral left rectal 
wall and at 2 cm above the dentate line. The surrounding 
mucosa proved to be healthy. Endoscopic observation 
suggested that the lesion probably originated in the 
connective tissue, transrectal ultrasound was therefore 
performed, together with an echo-guided needle-biopsy for 
the histological examination and a computed tomography 
(CT) with contrast medium of  the abdomen and the chest 
and an assay of  the carcinoembryonic antigen (CEA) and 
Ca19.9 tumoral markers.
Laboratory investigations revealed microcytic 
hypochromic anaemia, with haemoglobin of  11.9 g/dL, 
while CEA and Ca19.9 values were normal.
Transrectal ultrasound confirmed a predominantly 
exophytic, heterogenous, hypoechoic submucosal mass 
(measuring 35 mm × 26 mm) on the lateral left rectal 
wall (Figure 1). The histological examination of  the 
biopsy samples led to a diagnosis of  GIST due to the 
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immunohistochemical positivity for CD117 and CD34. 
Furthermore, there was also a mitotic activity of  a 3 × 50 
high power fi eld (HPF), together with moderate cytological 
atypia and absence of  necrosis. 
TC confirmed the sonographic findings of  the 
presence of  a mass with a marked, irregular, eccentric 
thickening of  the lateral left wall of  the lower third of  
the rectum, but there was no evidence for either pelvic 
lymphadenopathy or distant metastasis (Figure 2).
The patient underwent nerve-sparing, anterior surgical 
resection of  the rectum, with removal of  the mesorectum, 
followed by colo-anal anastomosis and the formation of  
a protective colostomy. The post-operative period was 
perfectly normal, with no complications, and the patient 
was sent home on d 10. The colostomy was closed up two 
months after surgery. 
Histological examination showed a submucous, 
intraparietal mass measuring 4 cm × 3 cm × 2 cm, with 
a central necrotic area and a completely healthy mucosa. 
The morphological aspect suggested a spindle-cell GIST, 
a diagnosis confirmed by the immunohistochemical 
investigation. Both CD117 and CD34 were, in fact, 
extremely positive (+++), and the mitotic index was < 5 × 
10 HPF. The neoplasia was 5 cm away from the margin of  
the distal resection. 
The patient did not undergo adjuvant therapy with 
imatinib. After 30 mo of  follow-up, he showed no signs of  
either local regression or distant metastases. 
DISCUSSION
GIST is an uncommon mesenchymal tumour located 
throughout the gastrointestinal tract and expresses CD117, 
a tyrosine-kinase growth factor receptor and the most 
important GIST marker[1]. CD117 also serves as the target 
for drug therapy with imatinib, a selective tyrosine-kinase 
receptor inhibitor that is at present the only promising 
chemotherapeutic drug for the treatment of  patients with 
advanced GIST, although complete surgical resection 
remains the most effective treatment for such a tumour[6].
GISTs are most commonly found in the stomach 
(60%-70%), followed by the small intestine (20%-25%), 
only about 5% of  all GISTs originate in the rectum[3,4]. 
The symptoms of  GIST in the rectum do not generally 
differ from those of  other rectal tumours and diagnostic 
work-up is also similar to that for any other rectal mass. 
Digital examination of  the rectum, colonoscopy and 
transrectal ultrasound are essential for its diagnosis, 
together with preoperative biopsy, which plays a key role 
in the diagnosis of  GIST, since it provides information 
on the immunohistochemical features and mitotic 
count. GIST typically expresses CD117, often CD34 
and sometimes SMA and S-100, but its expressions vary 
depending on different sites. Miettinen et al[7] found that 
CD34 expression in rectal GIST is 92%, but only 50% in 
small intestinal GIST. Smooth muscle antigen (SMA) is 
most frequently seen in the small intestinal GISTs (47%), 
whereas it has been observed in only 14% of  rectal GISTs. 
The reason for these variations has not yet been explained. 
Perhaps the differences in origin and their correlation with 
prognosis will be explained in the future. 
Although endoscopy provides the diagnosis and 
biopsy material, a definite diagnosis is difficult if  there 
is no mucosal invasion or extrinsic deformity. Most 
GISTs originate within the muscularis propria and most 
commonly have an exophytic growth pattern[8-10], seen on 
CT and MRI images. A focal, well-circumscribed mural 
mass is the most common finding and an infiltrated 
layer can be clearly assessed[11]. Furthermore, CT or MRI 
scanning is needed for the definition of  local invasion 
level and for the detection of  the presence of  possible 
metastases.  
Since the incidence of  rectal GIST is much lower 
than that of  GIST in the stomach or small intestine, 
the clinicopathological profiles of  rectal GIST have not 
yet been accurately characterised, and there is therefore 
the tendency to validate the same prognostic factors for 
the latter as for such tumours at other sites, particularly 
gastric GIST. The most important and easily applicable 
histological criteria for prediction of  GIST are its size 
and mitotic rate[12-15]. A rate of  ≤ 5 mitoses per 50 HPF 
is commonly used as a limit for a tumour with expected 
benign behaviour, and according to a large study, this 
can discriminate between benign and malignant tumours, 
especially gastric GISTs[12]. Tumours of  2 cm in diameter 
Figure 1  Transrectal ultrasound confirming a predominantly exophytic, 
heterogenous, hypoechoic submucosal mass (measuring 35 mm × 26 mm) on the 
lateral left rectal wall.
Figure 2  TC confi rming the sonographic fi ndings of the presence of a mass with 
a marked, irregular, eccentric thickening of the lateral left wall of the lower third of 
the rectum, but providing no evidence for either pelvic lymphadenopathy or distant 
metastasis.
are generally expected to behave in a benign fashion. 
Tumours of  < 5 cm in diameter are associated with a 
better survival rate than those of  5 cm-10 cm in diameter, 
which in turn have a better prognosis than those of  > 10 cm 
in diameter. Degrees of  cellularity and atypia have also 
been suggested as useful criteria, but their reproducibility 
is more problematic. The epithelioid phenotype, which 
seems to lead to a worse outcome, together with symptoms 
lasting for at least a year, might be considered as further 
prognostic factors. 
It is generally agreed that complete surgical resection 
with negative tumour margins is the principal curative 
procedure for primary and non-metastatic tumours, 
particularly for those at a low risk[8,16-18]. For rectal GIST, 
various surgical procedures may be considered, including 
local excision, anterior resection of  the rectum and 
abdomino-perineal resection. The choice of  procedure 
depends on tumour size and location[4,19]. Although not 
essential for the purpose of  oncological radicality, we 
ourselves prefer to remove the mesorectum, which makes 
it much easier to spare the nerves of  the lower hypogastric 
plexus, reduces intraoperative bleeding and guarantees 
more locoregional radicality, and this, in our opinion, also 
reduces the rate of  local relapse. Neoadjuvant imatinib 
may enhance the resectability of  inoperable malignant 
GIST and may allow for optimal surgical timing. Therapy 
with imatinib is also used in the adjuvant post-operative 
treatment of  tumours at a high risk or in cases of  
incomplete surgical resection. It has now been more or less 
accepted that imatinib is a valid treatment for advanced or 
metastatic tumours, but further evidence for the effi ciency 
of  this drug is needed in the case of  high risk tumours and 
for the neoadjuvant therapy.
In conclusion, rectal GIST should be included in 
differential diagnosis when a tumour in the rectum is 
detected although it is extremely rare. The diagnostic work-
up of  rectal GIST is exactly the same as that advised for 
any other type of  rectal neoplasia. There is no doubt that 
biopsy of  the tumour is an essential diagnostic instrument, 
since it can reach a certain preoperative diagnosis by means 
of  the immunohistochemical characterisation of  CD117 
and CD34. Finally, the lack of  a large series of  patients 
under long-term follow-up observations makes it diffi cult 
to assess the necessary extent of  surgical resection for 
rectal GIST and the indication for treatment with imatinib. 
Further studies are necessary to establish the most 
effective treatment strategy for patients with rectal GIST.
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